



Cite this: *Org. Biomol. Chem.*, 2017, **15**, 4440

Structural insights into the ene-reductase synthesis of profens†

J. Waller,^{‡a} H. S. Toogood,^{‡a} V. Karuppiiah,^a N. J. W. Rattray,^a D. J. Mansell,^a D. Leys,^a J. M. Gardiner,^{§a} A. Fryszkowska,^{§b} S. T. Ahmed,^a R. Bandichhor,^c G. P. Reddy^c and N. S. Scrutton^{†a}

Reduction of double bonds of α,β -unsaturated carboxylic acids and esters by ene-reductases remains challenging and it typically requires activation by a second electron-withdrawing moiety, such as a halide or second carboxylate group. We showed that profen precursors, 2-arylpropanoic acids and their esters, were efficiently reduced by Old Yellow Enzymes (OYEs). The XenA and GYE enzymes showed activity towards acids, while a wider range of enzymes were active towards the equivalent methyl esters. Comparative co-crystal structural analysis of profen-bound OYEs highlighted key interactions important in determining substrate binding in a catalytically active conformation. The general utility of ene reductases for the synthesis of (*R*)-profens was established and this work will now drive future mutagenesis studies to screen for the production of pharmaceutically-active (*S*)-profens.

Received 20th January 2017,
Accepted 26th April 2017

DOI: 10.1039/c7ob00163k

rscl.li/obc

Introduction

Biocatalysis is an important tool in sustainable chemicals production by enabling mild reaction conditions and often high stereo-, regio- and enantio-selectivity.¹ The ene reductases (ERs) are identified as important biocatalysts for asymmetric reduction of activated C=C bonds.² The flavin-containing NAD(P)H-dependent Old Yellow Enzyme (OYE) family of enzymes have been studied extensively for their biocatalytic potential due to their ability to catalyse the asymmetric reduction of activated C=C bonds to generate up to two stereogenic centres. *e.g.* ref. 2a and 3. Typical activating groups include keto, aldehyde and nitro-moieties,^{2a} in contrast to α,β -unsaturated mono-carboxylic acids and monoesters, which are typically poor substrates. In the latter case, reduction requires an additional electron-withdrawing group(s) conjugated to the double bond.^{3b,4}

Profens (2-arylpropanoic acids), such as naproxen ((*S*)-1), are important class of non-steroidal anti-inflammatory drugs

(NSAIDs), widely used to treat pain and inflammatory diseases such as osteo- and rheumatoid arthritis.⁵ There has been interest in developing new routes to the enantiomerically-pure 2-arylpropanoic acids. *e.g.* ref. 6. Recently, the use of ERs in the chemo-enzymatic synthesis of (*R*)-flurbiprofen (2) has been demonstrated,⁷ where the asymmetric C=C reduction of the precursor was achieved by the OYE YqjM from *Bacillus subtilis*. Several alternative biocatalytic strategies were proposed such as (i) self-sufficient H-borrowing cascades in which OYEs coupled to aldehyde dehydrogenases to convert α,β -unsaturated aldehydes to a diverse range of (chiral/achiral) α -substituted carboxylic acids⁸ or (ii) use of FMN and ferredoxin [4Fe-4S]-dependent clostridial enoate reductases, which can reduce weakly activated enoates.⁹

Here, we explored the reaction scope of ene reductases from OYEs and other enzyme classes^{2a} in profen synthesis from profen precursors (Scheme 1b and c). The experimental data was underpinned by the co-crystal structures of two oxidised OYEs XenA (from *Pseudomonas putida*)¹⁰ and NerA (from *Agrobacterium radiobacter*)¹¹ with 2-phenylacrylic acid 5b. This revealed the active site structural features crucial for substrate binding that will drive future structure-driven evolution of the enzymes in the synthesis of non-steroidal anti-inflammatory profens and related compounds.

Results and discussion

General

We studied the reduction of α,β -unsaturated carboxylic acids 5a–c by eight OYE family members¹² and a flavin-independent,

^aManchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. E-mail: nigel.scrutton@manchester.ac.uk

^bDr Reddy's Laboratories, Chiretech Technology Centre, 410 Cambridge Science Park Milton Rd, Cambridge CB4 0PE, UK

^cInnovation Plaza, IPDO Bachupally, Dr Reddy's Laboratories, Hyderabad-500090, India

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ob00163k

‡These authors contributed equally to the work.

§Current address: Merck Research Laboratories, Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065, USA.





Scheme 1 (A) Profens: (S)-naproxen **1a**, (R)-flurbiprofen **2**. (B) and (C) Proposed ene-reductase-catalysed steps in the chemoenzymatic synthesis of profens.

medium chain reductase, NtDBR, from *Nicotiana tabacum*.¹³ A prior study showed only a few ene-reductases were capable of reducing **5b**.¹⁴ We ran 6 OYE classical subclass members: PETNR,¹⁵ OYE2 and OYE3,¹⁶ GYE,¹⁷ LeOPR1,¹⁸ NerA¹⁹ as well as 2 thermophilic-like members XenA,²⁰ and TOYE²¹ (ESI Table S1† and Table 1 legends). These two subclasses differ in sequence length, key residue substitutions, oligomeric state and display distinct structural motifs.² Thermophilic OYEs have tetrameric or higher oligomeric states, shorter sequence lengths due to the loss of some surface loops and contain a highly-conserved, arginine finger involved in substrate binding.¹² Each enzyme contained either a N- or C-terminal His₆-tag (C-His₈ for PETNR) to enable rapid protein purification.

Enzymatic activity

Steady-state turnover reactions were performed with each purified enzyme using the known substrates ketoisophorone, 2-cyclohexen-1-one and nitrocyclohexene to check for native activity (ESI Table S1†). The specific activities of PETNR and NtDBR matched literature values, while TOYE and XenA showed a 40% and 30% reduction in activity, respectively. Subsequently two naproxen (**1**) precursors 2-(6-methoxynaphthalen-2-yl)acrylic acid **5a** and its methyl ester **3a** were tested (Table 1). Carboxylic acid products were converted into the equivalent methyl esters using trimethylsilyl diazomethane prior the GC analysis (ESI Fig. 1†). Out of 9 ene-reductases tested with substrate **5a** only XenA and GYE were active, showing 94–95% conversion to **1a**. Subsequently, we ran the reactions on 50 mg-scale with both XenA and GYE to isolate the product by preparative HPLC to confirm its structure by LCMS, ¹H NMR and chiral HPLC (ESI Fig. 2 and 3†). Unfortunately both XenA and GYE generated (R)-**1a** with high

Table 1 Biotransformations of ene-reductases with profens **3b** and **5a–c**

Substrate	Product	Enzyme	Conv. ^a (%)	ee ^b (%)
3a	(R)-4a	XenA	57	>99 (R)
		GYE	24	>99 (R)
		LeOPR1	21	>99 (R)
		TOYE	17	>99 (R)
		PETNR	9	>99 (R)
		NerA	3	>99 (R)
5a	(R)-1a	XenA	94	>99 (R)
		GYE	95	>99 (R)
5b	(R)-5c	XenA	97 ^c	>99 (R)
		GYE	44 ^b	>99 (R)
		YqjM ^d	95 ^d (ref. 7)	>99 (R)
5c	1c	XenA	7 ^{c,d}	N/D
		GYE	27 ^{c,d}	N/D

Reactions (1 mL) were performed in buffer (K₂HPO₄/KH₂PO₄ pH 7.5) containing the alkene (5 mM in 100% DMF), NADP⁺ (10 μM), D-glucose (15 mM), glucose dehydrogenase (GDH; 10 U) and enzyme (2 μM). Reactions were shaken at 30 °C for 24 h at 130 rpm. ^a Conv. = conversions. Quantitative analysis was performed on reactions extracted with ethyl acetate (0.9 mL) and derivatised with trimethylsilyl diazomethane to produce the respective methyl ester. Samples were analysed by GC using a ZB-semi volatiles column. ^b Enantiomeric excess was determined on reactions diluted 10-fold with acetonitrile, and analysed by HPLC using a Chiralpak AS-RH or Chiralpak AD-H column for **1a** or **4a**, respectively. ^c Reactions were performed in K₂HPO₄/KH₂PO₄ buffer pH 6.0. ^d Reactions were performed in 20 mM phosphate buffer containing 2-methyl-tetrahydrofuran. OYEs tested were PETNR = pentaerythritol tetranitrate reductase from *Enterobacter cloacae* PB2; LeOPR1 = 12-oxophytodienoate reductase 1 from *Solanum lycopersicum*; NerA = GTN reductase from *Agrobacterium radiobacter*; OYE2 from *Saccharomyces cerevisiae*; OYE3 from *Saccharomyces cerevisiae*; GYE from *Gluconobacter oxydans*; XenA = xenobiotic reductase from *Pseudomonas putida*; and TOYE = thermophilic Old Yellow Enzyme from *Thermoanaerobacter pseudethanolicus* E39. Due to quantity limitations of substrates **5a** to **5c**, they were only tested with OYEs active towards other profen precursors.

enantiopurity (>99% ee; ESI Fig. 4 and 5†), rather than the pharmacologically active (S)-enantiomer.

Six enzymes displayed activity towards methyl ester **3a** to give (R)-**4a** (Table 1 and ESI Fig. 6†). The highest conversion (54%) was obtained with XenA, while GYE, LeOPR1 and TOYE were 2–3-fold less active. PETNR and NerA showed <10% conversion. No (S)-selective enzyme was identified in this study.

OYEs XenA and GYE were subsequently tested with 2-(4-propylphenyl)acrylic acid **5b** and 2-phenylacrylic acid **5c**. Low conversions were obtained with substrate **5b** (Table 1), as determined previously with GYE in previous studies.¹⁴ No activity was detected with LeOPR1, however earlier work showed a slight (15% conversion) reaction with **5b**.¹⁴ In contrast, XenA and YqjM quantitatively reduced 2-phenylpropenoic acid **5b** to **5c**, with moderate conversion (44%) obtained with GYE (Table 1; ESI Fig. 7†). Reactions with the best enzymes were performed on a 50 mg-scale and the products were isolated by preparative HPLC. Structural identity was confirmed by ¹H NMR and



UHPLC-MS (ESI Fig. 8–10†). In comparison, prior studies of the reduction of the methyl ester derivative of **3b** by the OYE CLER from *Clavispora lusitanae* showed no activity.²² We tested all the OYEs and NtDBR with (*Z*)-but-2-enoic acid and methacrylic acid, but no activity was detected.

Structures of XenA and NerA bound to 2-phenylacrylic acid **5b**

We performed sequence (Fig. 1) and structural (Table 2 and Fig. 2) comparisons of XenA, NerA and other OYEs to explain the differences in their reactivity towards the substrates **3a** and **5a–c**. While XenA and YqjM belong to the thermophilic-like class, GYE is a classical OYE, indicating that the activity towards profens is not restricted to a single subclass of OYEs. We determined the co-crystal structures of XenA and NerA with 2-phenylacrylic acid **5b**, the latter inactive against this substrate. In spite of extensive crystallisation trials, no co-crystal structure of XenA or NerA could be obtained with naproxen precursor **5a** due to poor compound solubility in crystallisation solution. The data summary and refinement parameters for these structures are listed in Table 2. The structures enabled a comparison of substrate binding modes in both active and inactive conformations.

The overall crystal structure of XenA (Fig. 2A) is similar to the ‘thermophilic-like’ OYEs namely GkOYE from *Geobacillus kaustophilus*²⁴ (rmsd of 1.1 Å over 333 residues), YqjM¹² (rmsd of 1.1 Å over 332 residues), TsOYE from *Thermus scotoductus* SA-01²⁵ (rmsd of 1.2 Å over 348 residues), and TOYE from *Thermoanaerobacter pseudethanolicus* E39²¹ (rmsd of 1.2 Å over 331 residues). In this OYE subclass the functional unit is a homodimer, composed of two sets of monomeric active sites with the addition of a highly conserved ‘arginine finger’ residue (R333 in TOYE; Fig. 1) from an adjacent monomer.²¹ In the case of XenA, this conserved arginine is replaced by a tryptophan (W358; Fig. 2B). Comparisons with our previously determined XenA structures bound to nicotinamide biomimetics,^{3b} showed that the majority of the active site residues were relatively unchanged in position. The exception was W358 that was oriented away from the FMN, likely due to the presence of the bulky ligand **5b** (Fig. 2B). Interestingly, the position of

Table 2 X-ray data collection and refinement statistics for the co-crystal structures of XenA-**5b** and NerA-**5b**

Parameters	XenA- 5b (PDB 5N6Q)	NerA- 5b (PDB 5N6G)
Data collection		
Space group	<i>P</i> 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁
Unit cell dimensions	<i>a</i> = 57.39 Å, <i>b</i> = 84.04 Å, <i>c</i> = 155.97 Å; $\alpha = \beta = \gamma = 90^\circ$	<i>a</i> = 60.09 Å, <i>b</i> = 69.16 Å, <i>c</i> = 91.89 Å; $\alpha = \beta = \gamma = 90^\circ$
X-ray source	DLS ^a -I24	DLS ^a -I03
Wavelength (Å)	0.96862	0.97625
Resolution range (Å)	77.99–2.20 (2.27–2.20) ^b	91.89–1.58 (1.62–1.58) ^b
Multiplicity	3.5 (3.5)	6.3 (6.2)
<i>I</i> / σ <i>I</i>	5.6 (1.8)	12.1 (1.5)
Completeness (%)	98.4 (98.6)	99 (98.1)
<i>R</i> _{merge}	0.195 (0.982)	0.088 (1.14)
<i>R</i> _{meas}	0.230 (1.153)	0.106 (1.357)
<i>R</i> _{pim}	0.118 (0.592)	0.042 (0.535)
CC _{1/2}	0.982 (0.514)	0.998 (0.543)
Total observations	133 897 (11 604)	332 942 (23 776)
Total unique observations	38 419 (3290)	52 569 (3809)
Wilson <i>B</i> factor	18.269	14.638
Refinement		
<i>R</i> -work	0.1658	0.1404
<i>R</i> -free	0.2254	0.1641
RMS (bonds)	0.009	0.008
RMS (angles)	0.94	0.97
Average <i>B</i> -factor	25.6	23.9
Ramachandran plot statistics (%)		
Favored	95.46	97.82
Allowed	4.26	1.91
Outliers	0.28	0.27

^a Diamond light source. ^b Values in parentheses correspond to the higher resolution shell.

ligand **5b** in XenA is roughly equivalent to the location of NADPH mimics in other crystal structures.^{3b}

The aromatic ring and unsaturated carbons of **5b** are oriented parallel and facing the *si*-face of the non-covalently bound isalloxazine ring of FMN (Fig. 2B). The carbonyl oxygen and hydroxyl group are positioned to enable hydrogen bonds with residue atoms H178 NE, H181 ND and Y183 OH

Classical	OPR1	LAPL	TRQ	RSYG	IS	ETG	IGY	KDVP	G	FFCQ	IWHV	GRV	GVEI	HGAH	GYLIDQF	RDTF	YTS	DDP
	GYE	MSPL	TRGR	ADK	IS	REGL	GWPF	APG		IVCQ	LWHM	GRM	GVQI	HAANGY	LIDF	MKTW	YSQ	GP
	NCR	MAPL	TRGR	ATR	IS	QEG	LW	PYAP	G	IFAQ	LWHM	GRM	GVQI	HAANGY	LIDF	IETW	YTQ	TP
	NerA	MAPL	TRNR	SPG	31	IS	QGGQ	GYAD	VP	70	IVAQ	IWHV	GRI	104	GVEI	HAANGY	LIEQF	188
	PETNR	MAPL	TRLR	SIE		ISAQ	AKGY	AGAP	G	IAVQ	LWHT	GRI		LVEL	HAHGY	LLHQF		360
	MR	MAPL	TRS	RTPD		ISPT	ARGY	VYTP	G	IALQ	LWHV	GRV		MVEV	HAANA	CLPNQF		
	SYE1	MPPM	TRS	RSASQ		ISPT	AKGY	AWTP	G	IFAQ	LWHV	GRV		GIEL	HAANGY	LINQF		
Thermophilic	XenA	IPPM	CQY	MAED	31	VAPE	GRIT	PGCAG	72	PGIQ	IAHAG	RK	106	WIEL	HFAH	GYLG	QS	188
	TsOYE	MSPM	CQY	SATL		VEPL	GRIS	SPYDLG		PGIQ	LAHAG	RK		VIEL	HMAH	GYLL	SS	359
	GkOYE	MSPM	CMY	SCDT		VTPQ	GRIS	ERDLG		IGIQ	LAHAG	RK		VIEI	HAAH	GYLI	NEF	
	YQJM	MSPM	CMY	SSHE		VNPQ	GRIT	TDQDLG		IGIQ	LAHAG	RK		VIEI	HAAH	GYLI	NEF	
	TOYE	MSPM	CMY	SAST		VESR	GRIT	TDHDLG		MGIQ	LAHAG	RK		VVEI	HAAH	GYLI	NEF	

Fig. 1 Sequence alignment, using PROMALS3D,²³ showing selected regions covering the active site residues of ‘classical’ and ‘thermophilic-like’ class of OYEs. Active site residues are highlighted in green and red for classical and thermophilic-like OYEs respectively. Residue numbers are displayed for NerA and XenA.





Fig. 2 Structural comparisons of the co-crystal structures of XenA-5b and NerA-5b. (A) Overall structure of XenA, with the amino acids shown as ribbons with FMN (coral) and 5b (purple) as sticks. (B) Active site of XenA bound to ligand 5b. The side chains of residues that are up to 4 Å distance surrounding 5b are displayed. Trp358 in XenA, which is from the adjacent monomer, is labelled with an asterisk. The oxygen, nitrogen and phosphorous atoms are coloured red, blue and magenta respectively. The Fo–Fc omit maps (blue mesh) of FMN and 5b are contoured at 3σ . (C) Overall structure of NerA, with amino acids, FMN and 5b shown as in A. (D) Active site of NerA bound to ligand 5b with amino acids, FMN, 5b and omit maps as shown as in B. (E) Overlay of apo-NerA (4JIC, grey) and NerA-5b complex. The loop $\beta 3$ that shifts and adopts an anti-parallel β -strand in the NerA-5b complex is indicated by dotted lines. The PEG molecule (yellow) in the active site of apo-NerA was replaced by 5b (purple) and acetate (cyan) in the NerA-5b complex. (F) Orientation of 5b and FMN when XenA and NerA co-crystal structures were superimposed. The figure was generated using ccp4 mg.³¹

(Fig. 2B). Additionally, the carbonyl oxygen of 5b is 3.1 and 3.2 Å away from N3 and O2 atoms of FMN, respectively. Finally, the aromatic ring of 5b is stabilised by hydrogen bonding with residue Y27. Given that the C α and C β of the substrate is only 3.8 Å from the N5 atom of FMN, this suggests that the structure represents an active confirmation for C=C reduction.

The overall co-crystal structure of NerA (Fig. 2C), bound to 5b, is similar to the ‘classical’ OYEs such as PETNR²⁶ (rmsd of 1.3 Å over 354 residues), MR from *Pseudomonas putida* M10²⁷ (rmsd of 1.3 Å over 354 residues), NCR from *Zymomonas mobilis*²⁸ (rmsd of 1.3 Å over 350 residues), previous NerA structure²⁹ and SYE1 from *Shewanella oneidensis*³⁰ (rmsd of 1.6 Å over 355 residues). Similar to the XenA-5b structure, the monomeric NerA-5b complex looks similar to its respective apo structure.¹⁹ The residues lining the active site (Fig. 2D) are in a similar position as in the apo structure.¹⁹

As previously noted¹⁹ the long loop $\beta 3$, which partially caps the active site, is highly flexible as measured by the higher B-factors and the observation of weaker electron density for this region. Compared to the apo-structure, the loop $\beta 3$ in the

phenylacrylic acid-bound structure has significantly moved away from the active site (Fig. 2E).

This rearrangement has caused the side chain of residue T129 to be shifted closer to the aromatic ring of phenylacrylic acid 5b (Fig. 2D), a position occupied by F139 in the apo-structure. However the density for the side chain of Y129 indicates it likely occupies at least two different conformations, the second position located further away from the active site.

Phenylacrylic acid 5b is bound to the active site of NerA with the carbonyl oxygen and hydroxyl group position similar to the XenA-5b complex. As expected, the carbonyl oxygen of 5b forms hydrogen bonds with catalytic residues H178, N181 and Y183. Also, the hydroxyl moiety forms a hydrogen bond with a nearby water molecule. More importantly, the orientation of unsaturated carbons and the aromatic ring of 5b differ significantly from XenA-5b complex (Fig. 2F). This part of the molecule has flipped upwards and twisted away from the N5 atom of FMN, causing the aromatic ring of 5b to no longer be parallel to the isoalloxazine ring of FMN. This alternate orientation results in the formation of hydrogen bonds between the methylene group of 5b and OG atom of T125, and



one of the aromatic carbon atoms of phenylacrylic acid **5b** with the hydroxyl group of Y356. Crucially, this conformation in NerA has increased the distance between C β of **5b** and N5 of FMN to 4.12 Å, and positions it at a non-optimal angle for hydride attack. Therefore, this structure suggests that the absence of activity with **5b** could be due to ligand binding in an orientation not favoured for hydride transfer. The presence of the bulky side chain of Y27 in XenA would prevent substrate binding in a NerA-like conformation due to a clash with the aromatic ring of phenylacrylic acid **5b** (N27 in NerA).

A sequence alignment of different OYEs shows that Tyr27 is conserved only among the 'thermophilic-like' subgroup (Fig. 1), in which XenA, TOYE and YqjM belong. As TOYE is inactive towards **5b**, this suggests other residues and/or subtle active site features must play a role in determining if an OYE can bind **5b** in an active conformation, particularly when noting that GYE (active with **5b**) is a member of the classical subgroup of OYEs. Unfortunately, structural comparisons and/or docking models of GYE (pdb code: 3WJS) and other classical OYEs with **5b** were not possible (results not shown) as the known low resolution X-ray crystal structure of GYE is lacking its FMN cofactor.

Conclusions

OYEs are traditionally known to be inactive towards α,β -unsaturated carboxylic acids or methyl esters unless there is a second activating group conjugated to the double bond, such as halides or a second acid/methyl ester functionality.^{2a} We demonstrated that selected ene reductases from the OYE family are active towards α,β -unsaturated carboxylates **5a–c**. Analysis of the crystals structures XenA (active) and NerA (inactive) with **5b** highlighted subtle differences in active site and conformation, determining their ability to catalyse the double bond reduction.

Recent reports have highlighted the potential use OYEs in the semi-synthetic biosynthesis of medicinally-important chiral active profens, namely (*R*)-2.^{5b,32} Given that the pharmacologically active form in most cases are (*S*)-profens, knowledge of the substrate binding mode of precursor substrates could lead to rationally-guided OYE active site mutagenesis studies to generate (*S*)-selective profen products.

Experimental

General reagents and equipment

All solvents used were Fisher Optima LCMS grade, and formic acid was Aristar grade from VWR. Compounds naproxen **1a**, profen precursors methyl 2-(6-methoxynaphthalen-2-yl)propanoate **4a**, 2-phenylacrylic acid **5b** and 2-phenylpropionic acid **1b**, 2-(4-propylphenyl)acrylic acid **5c**, 2-(4-propylphenyl)propanoic acid **1c**, and the Codexis glucose dehydrogenase enzyme were kindly supplied by Dr Reddy's Laboratories EU via commercial suppliers. The concentration of nicotinamide

coenzymes (Melford) was determined by the extinction coefficient method ($\epsilon_{340} = 6220 \text{ M cm}^{-1}$). Steady-state kinetic analyses were performed on a Cary UV-50 Bio UV/Vis scanning spectrophotometer using a quartz cuvette (1 mL; Hellma) with a 1 cm path length. Anaerobic kinetics and biotransformation reactions were set up and/or monitored within an anaerobic glove box (Belle Technology Ltd) under a nitrogen atmosphere (<5 ppm oxygen). Prior to anaerobic reactions, enzymes were deoxygenated by passage through a BioRad 10DG column equilibrated in anaerobic reaction buffer. Samples for single molecule ¹H NMR analysis were dissolved in CDCl₃ and analysed on a Bruker 400 Hz NMR spectrophotometer. All spectra were compared to authentic standards.

Compound synthesis

Synthesis of methyl 2-(6-methoxynaphthalen-2-yl)acrylate 3a. Thionylchloride (0.788 mL, 10.96 mmol) was added to a stirred solution of (*S*)-2-(6-methoxynaphthalen-2-yl)propanoic acid (0.5 g, 2.19 mmol) in toluene (50 mL) and the resultant mixture refluxed for 4 h. The solution was cooled to 30 °C and concentrated to 10 mL followed by addition of methanol (30 mL) at 40 °C and stirring for an additional 2 h. The reaction was cooled to room temperature and washed with water (1 × 100 mL) and saturated sodium carbonate solution (2 × 50 mL). The organic layer was dried over magnesium sulphate and concentrated *in vacuo* to give the crude product as a yellow oil. The crude product was purified by column chromatography (Hex: EtOAc 4:1, $R_f = 0.45$) to afford the title compound as white crystals (0.162 g, 30%). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.88 (s, 1H, H-1), 7.44–7.79 (m, 2H), 7.52–7.55 (dd, 1H, $J = 8, 4 \text{ Hz}$, H-5), 7.16–7.21 (m, 2H), 6.44 (d, 1H, $J = 2 \text{ Hz}$, C=CH₂), 6.02 (d, 1H, $J = 2 \text{ Hz}$, C=CH₂), 3.95 (s, 3H), 3.89 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ ppm: 167.5 (C=O), 158.1 (C-6), 141.2, 134.3, 131.9, 129.8, 128.5, 127.3, 126.6, 119.1, 105.6, 55.3 (OCH₃), 52.2 (COOCH₃). NMR traces are located in the ESI (Fig. S15†).

Synthesis of 2-(6-methoxynaphthalen-2-yl)acrylic acid 5a. Selenium dioxide (41.2 g; 0.37 mol) was added to a solution of 1-(6-methoxynaphthalen-2-yl)ethan-1-one (50.0 g; 0.25 mol) in pyridine (213.5 mL) under N₂ and the mixture heated to 110 °C for 18 h. The mixture was cooled to room temperature and filtered, and the cake washed with EtOAc (100 mL). The combined filtrates were concentrated *in vacuo*. 2 M NaOH (4 volumes) was added to the residue, and the resultant solid filtered. This solid was suspended in water (300 mL), the pH adjusted to 1–2 with conc. HCl, and the solution extracted with EtOAc (3 × 250 mL). The combined organic phases were washed with water (250 mL), and evaporated. 2-(6-Methoxynaphthalen-2-yl)-2-oxoacetic acid (44.0 g; 76%) was recovered by filtration after trituration of the crude mass with *n*-heptane (50 mL). 2-(6-Methoxynaphthalen-2-yl)-2-oxoacetic acid (20.0 g; 87 mmol) was dissolved in anhydrous THF (100 mL) under N₂ and cooled to –30 °C. Methyl magnesium chloride (1.0 M in THF; 132 mL; 0.13 mol) was added dropwise whilst maintaining the temperature below –20 °C, and the reaction stirred out for 2 h between –20 and –30 °C. The reac-



tion was quenched by careful addition of conc. HCl (30 mL) at 0–5 °C, then water (80 mL) was added and the mixture stirred out for 30 min, filtered, and the cake washed with EtOAc (300 mL). The phases in the filtrate were separated, and the aqueous phase extracted with EtOAc (100 mL). The combined organic phases were washed with water (2 × 60 mL) and concentrated to ~40 mL total volume. *n*-Heptane (80 mL) was added and the mixture filtered. The cake was washed with *n*-heptane (20 mL) and dried to give 2-(6-methoxynaphthalen-2-yl)acrylic acid (14.0 g, 71%). ¹H NMR (400 MHz, *d*₆-DMSO) δ ppm: 7.9 (d, 1H, *J* = 1.2 Hz, H-1), 7.84 (d, 1H, *J* = 9.2 Hz), 7.79 (d, 1H, *J* = 8.8 Hz), 7.53 (d, 1H, *J* = 8.6 Hz, 1.8 Hz), 7.31 (d, 1H, *J* = 2.4 Hz, H-5), 7.16 (dd, 1H, *J* = 8.8 Hz, 2.6 Hz, H-7), 6.26 (d, 1H, ²*J* = 1 Hz, C=CH₂), 6.06 (d, 1H, ²*J* = 1 Hz, C=CH₂), 3.86 (s, 3H, OCH₃). ¹³C NMR (100 MHz, CDCl₃) δ ppm: 168.0 (C=O), 157.6 (C-6), 141.4, 133.8, 131.7, 129.7, 127.9, 126.8, 126.5, 126.3, 125.5, 118.8, 105.6, 55.2 (OCH₃). NMR traces are located in the ESI (Fig. S15†).

Enzyme production and purification

The OYEs investigated were the following: (i) PETNR from *Enterobacter cloacae* PB2, (ii) TOYE from *Thermoanaerobacter pseudethanolicus* E39, (iii–iv) OYE2 and OYE3 from *Saccharomyces cerevisiae*, (v) NerA from *Agrobacterium radiobacter*, (vi) XenA from *Pseudomonas putida*, (vii) GYE from *Gluconobacter oxydans* and (viii) LeOPR1 from *Solanum lycopersicum*.³³ The flavin-independent double bond reductase NtDBR from *Nicotiana tabacum* was also used in this study.¹³ The enzymes XenA, NerA and LeOPR1 were cloned into plasmid pET21a, while OYE2, OYE3, TOYE and NtDBR were expressed in pET21b. GYE was supplied in a pET28b plasmid, while the C-terminally His₈-tagged PETNR gene³⁴ was cloned into pBluescript SK⁺ (Stratagene) under the control of a native *lac* promoter.³⁵ All constructs contained a C-terminal His_{6/8}-tag, and were expressed in the *Escherichia coli* strain BL21 (DE3) except for PETNR and TOYE which were expressed in JM109 and Arctic Express strains, respectively.

All ene-reductases were produced and purified using the same general protocol. Starter cultures (5 mL and 20 mL) were produced overnight in lysogeny broth (LB) containing glucose (0.2%) and ampicillin (100 μ g mL⁻¹; 15 μ g mL⁻¹ kanamycin for GYE). The starter cultures were used to inoculate terrific broth (TB; 12 × 1 L per enzyme) containing glucose (2%), and incubated at 37 °C and 190 rpm until mid log phase (OD 600 nm ~ 0.5). Recombinant protein expression was induced by the addition of IPTG (10 μ M), followed by incubation overnight at 25 °C (18 °C for TOYE), at 190 rpm. Cells were harvested by centrifugation for 10 min at 5000g at 4 °C, and the supernatant discarded. The cell pellets were frozen in liquid nitrogen and stored at –80 °C.

The cells were resuspended in lysis buffer (50 mM KH₂PO₄/K₂HPO₄ pH 8.0) containing 1× protease inhibitor cocktail (Roche) and DNase (10 μ g mL⁻¹) and lysozyme (10 μ g mL⁻¹). Excess free FMN was added to the OYE cell slurries to increase the degree of flavination of the enzymes. The cells were lysed using a sonicator (Bandelin) with a probe set at 40%

amplitude with cycles of 10 s ON and 10 s OFF for 12 min. The lysed cells were centrifuged at 18 000g for 1 h and the supernatant was passed through a 0.2 micron filter. NaCl (300 mM) and imidazole (10 mM) were added, and the extracts were passed through Nickel Sepharose affinity column (20 mL), pre-equilibrated in equilibration buffer (50 mM KH₂PO₄/K₂HPO₄ pH 8.0, 300 mM NaCl, 10 mM imidazole). The column was washed with wash buffer (50 mM KH₂PO₄/K₂HPO₄ pH 8.0, 300 mM NaCl, 20 mM imidazole; 200 mL) followed by elution buffer (50 mM KH₂PO₄/K₂HPO₄ pH 8.0, 300 mM NaCl, 300 mM imidazole, 150 mL). In some cases an additional nickel Sepharose purification step was performed, as detailed above, to increase the protein purity. Protein purity was assessed by SDS-PAGE, using 10–12% Mini-PROTEAN® TGX Stain-Free™ gels and Precision Plus protein unstained markers (BioRad) according to the manufacturer's instructions. Purified protein was desalted and concentrated using Vivaspin tubes (10 000 MW cut-off). Protein concentrations of each OYE was determined using the extinction coefficient method with the following values (M cm⁻¹): PETNR ϵ_{464} = 11 300; TOYE ϵ_{456} = 11 300; OYE2 ϵ_{462} = 10 600; OYE3 ϵ_{464} = 10 600; GYE ϵ_{450} = 11 300; XenA ϵ_{450} = 11 300; NerA ϵ_{450} = 11 300 and LeOPR1 ϵ_{450} = 11 300. Enzyme NtDBR protein concentration was determined by the Bradford method.³⁶ Aliquots of enzyme were flash frozen in liquid nitrogen and stored in fractions at –80 °C.

Steady state kinetics

Standard ene-reduction reactions (1 mL) were performed anaerobically in buffer (50 mM K₂HPO₄/KH₂PO₄) containing alkene (1 mM) and NADPH (100 μ M) at 25 °C at the reported pH optimum for each enzyme. The reaction was initiated by addition of the oxidative substrate and the loss of NADPH was monitored continuously at OD 340 nm. The substrates tested were ketosiphorone, 2-cyclohexen-1-one and nitrocyclohexene, and the results were compared to literature values where available. Initial rates were determined using Cary WinUV software and expressed as specific activity (μ mol min⁻¹ mg⁻¹).

Biotransformation reactions

Biotransformation reactions (1.0 mL) were performed anaerobically in buffer (K₂HPO₄/KH₂PO₄ pH 7.5) containing the alkene (5 mM in 100% DMF), NADP⁺ (10 μ M), D-glucose (15 mM), glucose dehydrogenase (GDH; 10 U) and enzyme (2 μ M). Reactions were shaken at 30 °C for 24 h at 130 rpm and terminated by extraction with ethyl acetate (0.9 mL) for achiral GC analysis, or diluted 10-fold with acetonitrile for chiral HPLC analysis. Scaled up reactions (50 mg) were performed using the same molarities as standard reactions and were incubated for 48 h. All biotransformation reactions were performed in at least duplicates, and the results are averages of the data.

Analysis of biotransformations

Carboxylic acids **1a–b** and **5a–b** were converted to methyl esters using trimethylsilyl diazomethane prior to analysis. The biotransformation mixture (500 μ L) was acidified to pH 5 using 1 M HCl and extracted into ethyl acetate (500 μ L).



Methanol (50 μL) was then added followed by trimethylsilyl diazomethane (10 μL). The mixtures were incubated for 20 min at 25 $^{\circ}\text{C}$ then quenched by the addition of glacial acetic acid (5 μL).

The conversions and yields were determined by GC (Agilent Technologies 7890A system with FID detector) using limonene as an internal standard (0.5%): ZB-semi volatiles column (30 m; 0.25 mm; 0.25 μm film thickness; Phenomenex); injector 220 $^{\circ}\text{C}$, split ratio of 20 : 1; 1 μL injection, 5 psi, flow 1 mL min^{-1} (helium); oven: 80 $^{\circ}\text{C}$ (2 min), 30 $^{\circ}\text{C min}^{-1}$ to 300 $^{\circ}\text{C}$, hold (3 min). Quantitative analysis was carried using calibration curves.

Chiral analysis of the products was performed by HPLC (Agilent 1100 m with diode array detection, λ 220 nm) and compared to authentic standards of enantiomers. Compounds **1a** and **5a**: Chiralpak AS-RH (150 $\times$ 4.6 mm ID), 20 $^{\circ}\text{C}$, MeCN : H₂O (40 : 60), 0.8 mL min^{-1} , Rt: (S)-**1a** 4.1 min; (R)-**1a** 4.6 min. Compound **5b**: Chiralpak AD-H (150 $\times$ 4.6 mm ID), 20 $^{\circ}\text{C}$, hexane : isopropanol (95 : 5), 1 mL min^{-1} , Rt: (R)-**1b** 8.1 min; (S)-**1b** 9.2 min. Preparative HPLC purification of **1a** was performed using Phenomenex Luna C18 column (5 μm $\times$ 21.2 $\times$ 250 mm) at 15 mL min^{-1} using a gradient of MeCN : H₂O 10 : 90 to 50 : 50 over 15 min. ¹H NMR analysis is presented in ESI Fig. S10–S13.†

UHPLC-MS analysis was performed using a Dionex U3000 RSLC system equipped with a Thermo-Fisher Q-Exactive Plus detector, 5 μL injection. All analysis was carried out in positive ionisation mode using Thermo Fisher Accucore C₁₈ column (2.6 μm $\times$ 2.1 mm $\times$ 100 mm); average peak 6 s; 0.5 mL min^{-1} ; mobile phase: A (95% H₂O 5% MeOH 0.1% formic acid) and B (95% MeOH 5% H₂O 0.1% formic acid); gradient A : B: 95 : 5 (hold 2 min) to 5 : 95 over 3 min (hold 2 min), to 95 : 5 over 1 min (hold 2 min).

Protein crystallography

XenA and NerA were concentrated to 15 mg mL^{-1} and 23 mg mL^{-1} respectively. Crystallisation trials were set up using a Mosquito robot (TTP Labtech) by dispensing 200 nL of both protein and crystallisation solution. XenA and NerA crystals were obtained in crystallisation solution A (0.2 M sodium iodide, 0.1 M Bis-Tris propane pH 7.5 and 20% (w/v) PEG 3350) and B (0.1 M sodium acetate, 1 M lithium chloride, 30% (w/v) PEG 6000), respectively. Crystals were incubated with 25 mM **5b** dissolved in their respective mother liquors and supplemented with 20% glycerol for 10 min. Crystals were cryo-cooled in liquid nitrogen prior to data collection.

Structure solution for XenA and NerA

X-ray diffraction data were collected at Diamond Light Source beamlines I03 and I24. The NerA dataset was processed using the automated data reduction pipeline in xia2³⁷ using XDS⁴¹ to 1.58 Å. The XenA dataset was manually processed using MOSFLM³⁸ and Aimless,³⁹ as implemented in ccp4,⁴⁰ to 2.2 Å. The **5b**-bound structures of XenA and NerA were solved by molecular replacement using XenA (modified 5bPM) and NerA (modified 4JIC) coordinates, respectively, as search models in

Phaser.⁴¹ The models were built and refined using Phenix.⁴² The structures were completed by iterative cycles of manual model building in Coot⁴³ and refinement using phenix.refine.⁴⁴ The structures were validated using PDB_REDO⁴⁵ and Molprobity.⁴⁶ The data summary and refinement parameters are listed in Table 2. The atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB codes 5N6Q (XenA) and 5N6G (NerA)).

Acknowledgements

We thank Diamond Light Source for access to beamlines I03 and I24 (proposal number mx12788). We thank Dr Colin Levy, Manchester Protein Structure Facility (MPSF), for help with X-ray data collection. We thank Alexander Geddes for help with protein purification. This work was funded and supported by the UK Biotechnology and Biological Sciences Research Council (BB/I015779/1), Dr Reddy's Laboratories and Centre for Synthetic Biology of Fine and Speciality Chemicals (SynBioChem; BBSRC: BB/M017702/1). NSS was a Royal Society Wolfson Merit Award holder and is an Engineering and Physical Sciences Research Council (EPSRC; EP/J020192/1) Established Career Fellow.

Notes and references

- 1 P. J. Dunn, *Chem. Soc. Rev.*, 2012, **41**, 1452.
- 2 (a) H. S. Toogood, J. M. Gardiner and N. S. Scrutton, *ChemCatChem*, 2010, **2**, 892; (b) H. S. Toogood, D. Mansell, J. M. Gardiner and N. S. Scrutton, in *Comprehensive Chirality Vol. 7*, Elsevier Science, Oxford, 1., 2011, p. 216.
- 3 (a) E. Brenna, G. Fronza, C. Fuganti, D. Monti and F. Parmeggiani, *J. Mol. Catal. B: Enzym.*, 2011, **73**, 17; (b) T. Knaus, C. E. Paul, C. W. Levy, S. de Vries, F. G. Mutti, F. Hollmann and N. S. Scrutton, *J. Am. Chem. Soc.*, 2016, **138**, 1033; (c) H. S. Toogood and N. S. Scrutton, *Curr. Opin. Chem. Biol.*, 2014, **19**, 107; (d) M. Hall and A. S. Bommarius, *Chem. Rev.*, 2011, **111**, 4088.
- 4 (a) S. Koul, D. H. G. Crout, W. Errington and J. Tax, *J. Chem. Soc., Perkin Trans. 1*, 1995, 2969; (b) H. S. Toogood, A. Fryszkowska, V. Hare, K. Fisher, A. Roujeinikova, D. Leys, J. M. Gardiner, G. M. Stephens and N. S. Scrutton, *Adv. Synth. Catal.*, 2008, **350**, 2789; (c) C. K. Winkler, G. Tasnadi, D. Clay, M. Hall and F. Faber, *J. Biotechnol.*, 2012, **162**, 381.
- 5 (a) A. M. Evans, *J. Clin. Pharmacol.*, 1996, **36**, 7S; (b) K. C. Duggan, D. J. Hermanson, J. Musee, J. J. Prusakiewicz, J. L. Scheib, B. D. Carter, S. Banerjee, J. A. Oates and L. J. Marnett, *Nat. Chem. Biol.*, 2011, **7**, 803.
- 6 (a) H. Alper, A. Eisenstat and N. Satyanarayana, *J. Am. Chem. Soc.*, 1990, **112**, 7060; (b) C. Giordano, S. Castaldi, S. Cavicchioli and M. Villa, *Tetrahedron*, 1989, **45**, 4243; (c) P. J. Harrington and E. Lodewijk, *Org. Process Res. Dev.*, 1997, **1**, 72; (d) I. T. Harrison, B. Lewis, P. Nelson, W. Rooks, A. Roszkowski, A. Tomolonis and J. H. Fried,



- J. Med. Chem.*, 1970, **13**, 203; (e) T. Hiyama, M. Wakasa and T. Kutumoso, *Synlett*, 1991, 569; (f) T. Ohta, H. Takaya, M. Kitamura, K. Nagai and R. Noyori, *J. Org. Chem.*, 1987, **52**, 3174; (g) T. V. RajanBabu and A. L. Casalnuovo, *J. Am. Chem. Soc.*, 1992, **114**, 6265; (h) H. R. Sonawane, N. S. Bellur, J. R. Ahuja and D. G. Kulkarni, *Tetrahedron: Asymmetry*, 1992, **3**, 163.
- 7 J. Pietruszka and M. Schölzel, *Adv. Synth. Catal.*, 2012, **354**, 751.
 - 8 T. Knaus, F. G. Mutti, L. D. Humphreys, N. J. Turner and N. S. Scrutton, *Org. Biomol. Chem.*, 2014, **13**, 223.
 - 9 (a) S. Nizam, R. K. Gazara, S. Verma, K. Singh and P. K. Verma, *PLoS One*, 2014, **9**, e95989; (b) F. Rohdich, A. Wiese, R. Feicht, H. Simon and A. Bacher, *J. Biol. Chem.*, 2001, **276**, 5779; (c) A. Fryszkowska, K. Fisher, J. M. Gardiner and G. Stephens, *Org. Biomol. Chem.*, 2010, **8**, 533.
 - 10 D. S. Blehert, B. G. Fox and G. H. Chambliss, *J. Bacteriol.*, 1999, **181**, 6254.
 - 11 J. R. Snape, N. A. Walkley, A. P. Morby, S. Nicklin and G. F. White, *J. Bacteriol.*, 1997, **179**, 7796.
 - 12 K. Kitzing, T. B. Fitzpatrick, C. Wilken, J. Sawa, G. P. Bourenkov, P. Macheroux and T. Clausen, *J. Biol. Chem.*, 2005, **280**, 27904.
 - 13 D. J. Mansell, H. S. Toogood, J. Waller, J. M. X. Hughes, C. W. Levy, J. M. Gardiner and N. S. Scrutton, *ACS Catal.*, 2013, **3**, 370.
 - 14 T. Reiß, W. Hummel, S. P. Hanlon, H. Iding and H. Gröger, *ChemCatChem*, 2015, **7**, 1302.
 - 15 A. Fryszkowska, H. Toogood, M. Sakuma, J. M. Gardiner, G. M. Stephens and N. S. Scrutton, *Adv. Synth. Catal.*, 2009, **351**, 2976.
 - 16 M. Hall, C. Stueckler, B. Hauer, R. Stuermer, T. Friedrich, M. Breuer, W. Kroutil and K. Faber, *Eur. J. Org. Chem.*, 2008, 1511.
 - 17 N. Richter, H. Gröger and W. Hummel, *Appl. Microbiol. Biotechnol.*, 2011, **89**, 79.
 - 18 C. Stueckler, M. Hall, H. Ehammer, E. Pointner, W. Kroutil, P. Macheroux and K. Faber, *Org. Lett.*, 2007, **9**, 5409.
 - 19 G. Oberdorfer, A. Binter, S. Wallner, K. Durchschein, M. Hall, K. Faber, P. Macheroux and K. Gruber, *ChemBioChem*, 2013, **14**, 836.
 - 20 Y. Yanto, H. H. Yu, M. Hall and A. S. Bommarius, *Chem. Commun.*, 2010, **46**, 8809.
 - 21 B. V. Adalbjörnsson, H. S. Toogood, A. Fryszkowska, C. R. Pudney, T. A. Jowitt, D. Leys and N. S. Scrutton, *ChemBioChem*, 2010, **11**, 197.
 - 22 Y. Ni, H.-L. Yu, G.-Q. Lin and J.-H. Xu, *Enzyme Microb. Technol.*, 2014, **56**, 40.
 - 23 J. M. Pei and N. V. Grishin, *Methods Mol. Biol.*, 2014, **1079**, 263.
 - 24 M. Schittmayer, A. Glieder, M. K. Uhl, A. Winkler, S. Zach, J. H. Schrittwieser, W. Kroutil, P. Macheroux, K. Gruber, S. Kambourakis, J. D. Rozzell and M. Winkler, *Adv. Synth. Catal.*, 2011, **353**, 268.
 - 25 D. J. Opperman, B. T. Sewell, D. Litthauer, M. N. Isupov, J. A. Littlechild and E. van Heerden, *Biochem. Biophys. Res. Commun.*, 2010, **393**, 426.
 - 26 H. S. Toogood, A. Fryszkowska, M. Hulley, M. Sakuma, D. Mansell, G. M. Stephens, J. M. Gardiner and N. S. Scrutton, *ChemBioChem*, 2011, **12**, 738.
 - 27 C. R. Pudney, S. Hay, J. Y. Pang, C. Costello, D. Leys, M. J. Sutcliffe and N. S. Scrutton, *J. Am. Chem. Soc.*, 2007, **129**, 13949.
 - 28 S. Reich, H. W. Hoeffken, B. Rosche, B. M. Nestl and B. Hauer, *ChemBioChem*, 2012, **13**, 2400.
 - 29 G. Oberdorfer, A. Binter, S. Wallner, K. Durchschein, M. Hall, K. Faber, P. Macheroux and K. Gruber, *ChemBioChem*, 2013, **14**, 836.
 - 30 D. van den Hemel, A. Brige, S. N. Savvides and J. Van Beeumen, *J. Biol. Chem.*, 2006, **281**, 28152.
 - 31 S. McNicholas, E. Potterton, K. S. Wilson and M. E. Noble, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2011, **67**, 386.
 - 32 J. L. Eriksen, S. A. Sagi, T. E. Smith, S. Weggen, P. Das, D. C. McLendon, V. V. Ozols, K. W. Jessing, K. H. Zavitz, E. H. Koo and T. E. Golde, *J. Clin. Invest.*, 2003, **112**, 440.
 - 33 J. Straßner, A. Fürholz, P. Macheroux, N. Amrhein and A. Schaller, *J. Biol. Chem.*, 1999, **274**, 35067.
 - 34 M. E. Hulley, H. S. Toogood, A. Fryszkowska, D. J. Mansell, G. M. Stephens, J. M. Gardiner and N. S. Scrutton, *ChemBioChem*, 2010, **11**, 2433.
 - 35 R. E. Williams and N. C. Bruce, *Microbiology*, 2002, **148**, 1607.
 - 36 G. L. Peterson, *Methods Enzymol.*, 1983, **91**, 95.
 - 37 G. Winter, C. M. Lobley and S. M. Prince, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2013, **69**, 1260.
 - 38 H. R. Powell, O. Johnson and A. G. W. Leslie, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2013, **69**, 1195.
 - 39 P. R. Evans and G. N. Murshudov, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2013, **69**, 1204.
 - 40 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. S. Wilson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2011, **67**, 235.
 - 41 A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and R. J. Read, *J. Appl. Crystallogr.*, 2007, **40**, 658.
 - 42 P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H. Zwart, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 213.
 - 43 P. Emsley, B. Lohkamp, W. G. Scott and K. Cowtan, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 486.
 - 44 P. V. Afonine, R. W. Grosse-Kunstleve, N. Echols, J. J. Headd, N. W. Moriarty, M. Mustyakimov, T. C. Terwilliger, A. Urzhumtsev, P. H. Zwart and



- P. D. Adams, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2012, **68**, 352.
- 45 R. P. Joosten, F. Long, G. N. Murshudov and A. Perrakis, *IUCrJ*, 2014, **1**, 213.
- 46 V. B. Chen, W. B. Arendall III, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral, L. W. Murray, J. S. Richardson and D. C. Richardson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, **66**, 12.

